Most GLP-1 programs have a pricing problem they don’t talk about openly. The problem isn’t the starting price — that often looks reasonable. The problem is what happens when your dose goes up, which it will, because that’s how GLP-1 therapy works.
You start low. Your physician titrates you upward over weeks and months until you reach the therapeutic dose that’s right for your body. That’s not optional. It’s the protocol. And in most programs, every step up the titration ladder costs you more money.
That’s a broken model. And it creates incentives that work against your treatment.
How GLP-1 Dosing Actually Works
Semaglutide and tirzepatide aren’t medications you take at a fixed dose forever. They’re titrated — started low to minimize side effects, then gradually increased until you reach a dose that meaningfully suppresses appetite and produces sustainable GLP-1 weight loss.
A standard semaglutide titration might look like this:
- 0.25mg weekly for four weeks
- 0.5mg for four weeks
- 1mg for four weeks
- 1.7mg for four weeks
- 2.4mg maintenance
Your Dose Is a Clinical Variable
Some patients respond well at lower doses and stay there. Others need to reach the top of the range to see meaningful results. Your physician determines this through your response — how you’re tolerating the medication, how your body is reacting, what your weight trajectory looks like.
The point is: your dose is a clinical variable. It moves. It should move. And your monthly cost should have nothing to do with it.
What Variable Pricing Does to Your Treatment
Here’s what happens when a program charges more for higher doses: patients start making clinical decisions based on price.
They stay at a lower dose longer than clinically indicated — not because their physician recommends it, but because bumping up to the next tier means an extra $30, $50, $100 a month. They plateau. They see slower results. Some quit entirely, attributing the failure to the medication when the actual problem was a financial barrier to proper dosing.
This isn’t hypothetical. It’s the predictable consequence of price architecture that penalizes therapeutic progress.
The Incentive Problem
A model that makes treatment more expensive as it becomes more effective is not a wellness program. It’s a billing structure that happens to involve medication.
When the platform earns more revenue every time your dose goes up, the platform is not financially neutral about whether your dose should go up. That’s not a conspiracy. That’s just incentives.
The Flat-Price Case
LegacyRx charges a flat monthly rate for GLP-1 weight loss — a rate that doesn’t change when your dose does.
You start at 0.25mg. Your physician titrates you based on how your body responds — 1mg, 1.7mg, 2.4mg — until you reach the level that works for you. The dose is a clinical decision made with your physician, and your monthly cost depends on the plan you choose.
This matters enormously in practice. It means your physician can recommend the dose they actually believe is right for you without either of you factoring cost into the clinical calculus. It means you’re not rationing your own treatment. It means the program is aligned with your outcome, not with billing optimization.
For anyone getting an online GLP-1 prescription, this distinction is worth understanding before you enroll.
Why Most Programs Don’t Structure It This Way
The most direct answer is that variable pricing is more profitable. If you charge by dose tier, your highest-use patients — the ones who need the medication most and are seeing the most progress — generate the most revenue.
There’s also an argument that higher doses genuinely cost more to compound and dispense. That’s not wrong. But the question is whether the patient should absorb that variability, or whether the program should engineer around it. We’ve chosen to engineer around it because predictable cost is better for adherence, better for outcomes, and more honest about what we’re building.
Flat monthly pricing isn’t a promotion. It’s a structural commitment to keeping your cost predictable, with no hidden fees and no membership charges.
What to Ask Before You Enroll in Any GLP-1 Program
If you’re evaluating GLP-1 programs — and you should be, this is your health and your money — here are the questions worth asking:
- What does my monthly price look like at 1mg? At 2.4mg? If the answer changes significantly between those two numbers, understand why before you commit.
- Does the program offer a price guarantee, or is pricing subject to change? Short-term introductory pricing that ratchets up once you’re established is common. Know the long-term number.
- Is the prescribing physician independent of the platform’s billing model? Physicians whose revenue is tied to a platform’s billing model are not structurally independent.
- What’s the protocol if I need to adjust my dose downward? Progress isn’t always linear. A good compounded semaglutide program accounts for that without penalizing you financially.
Alignment Is Everything
A good pricing model is the one most directly aligned with your outcome. Flat pricing means the program makes the same revenue whether you’re at 0.25mg or 2.4mg, so the focus stays on helping you achieve the result you came for — under a licensed physician’s care.
One more thing worth knowing: compounded semaglutide and tirzepatide are not FDA-approved. That’s why the pharmacy’s licensing, the physician’s review, and the quality of the program behind them matter so much when you compare options.
Your dose is a clinical decision. It should stay that way.
See If LegacyRx Is Right for You
Flat monthly pricing with no hidden fees. U.S.-licensed physicians. State-licensed compounding pharmacies. Free discreet shipping. GLP-1 programs start at $168.90/month. Not everyone qualifies; a licensed physician decides if treatment is right for you.